Key statistics
On Friday, Ionis Pharmaceuticals Inc (0JDI:LSE) closed at 81.40, -6.13% below its 52-week high of 86.72, set on Feb 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 81.40 |
| Low | 81.40 |
| Bid | -- |
| Offer | -- |
| Previous close | 82.43 |
| Average volume | 968.00 |
|---|---|
| Shares outstanding | 161.97m |
| Free float | 160.88m |
| P/E (TTM) | -- |
| Market cap | 13.06bn USD |
| EPS (TTM) | -1.71 USD |
Data delayed at least 20 minutes, as of Feb 13 2026 18:50 GMT.
More ▼
Press releases
- Ionis to hold fourth quarter and full year 2025 financial results webcast
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
- Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
- Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
- Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
- Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
More ▼
